Travere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 48.2%, EPS fell 164.3%, free cash flow grew 604.2% and total debt rose 93.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow TVTX
Travere Therapeutics, Inc. (TVTX) EV/Sales
As of 16 October 2026, Travere Therapeutics, Inc. (TVTX) trades at a EV/Sales of 8.0×. Over the past ten years it has ranged from 1.3× (March 2020) to 22.0× (March 2015); the current reading is higher than 76% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.9× | 22.88% |
| FY2024 | 5.6× | 57.25% |
| FY2023 | 3.6× | (68.44%) |
| FY2022 | 11.4× | (2.24%) |
| FY2021 | 11.6× | 100.31% |
| FY2020 | 5.8× | 149.39% |
| FY2019 | 2.3× | (40.21%) |
| FY2018 | 3.9× | (2.15%) |
| FY2017 | 4.0× | 12.66% |
| FY2016 | 3.5× | (23.67%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 9.2× | 77.12% |
| Mar 2026 | 5.2× | (25.20%) |
| Dec 2025 | 6.9× | 37.83% |
| Sep 2025 | 5.0× | 28.24% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DFTX Definium Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| ORKA Oruka Therapeutics, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 5.6× |
| TVTX Travere Therapeutics, Inc. | 8.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | 8.7× |
| SRRK Scholar Rock Holding Corporation compare | 104× |
| COGT Cogent Biosciences, Inc. compare | 193× |
| CRSP CRISPR Therapeutics AG compare | 223× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)